Early Access — free while we kick the tires
EdgarHawk

Hamilton Thomas Edward

Director

Director
1 filing analyzed · 1 company · Latest 2026-03-02

Companies

Company Buys Sells Direction
Larimar Therapeutics, Inc. LRMR 1 0 Net buying

Activity

March 2026
medium
Buy
100,000 shares
$500,000
Significance 5/10

Director Hamilton Thomas Edward bought 100,000 LRMR shares at $5.00 for $500,000; cluster of 3 concurrent insiders also buying amid unprofitable operations.

Hamilton Thomas Edward (Director) purchased 100,000 shares at $5.00 on 2026-02-27, increasing his holdings by 17.7% to 664,798 shares total. This transaction is part of a cluster pattern: 3 other insiders also bought within the past 14 days. Against this backdrop, the company reported zero revenue in its latest quarter and negative net income of -$47,712,000.00, with an overall unprofitable fiscal year. The stock has appreciated 47.7% over 30 days and 67.6% over 90 days from unnamed reference points, though it remains 12.1% below its 52-week high of $5.95. Notably, this director's prior buy at LRMR on 2024-02-16 generated negative 90-day returns of -15.0%, and his cross-ticker track record shows a 0.00% win rate on buys with an average 90-day return of -15.0%, suggesting a pattern of poor timing on purchase decisions. The concurrent buying activity by multiple insiders, while potentially signaling internal optimism, occurs in a fundamentally challenged environment and must be weighed against the insider's historical execution record.

Related insiders

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access